“How about firms like Greenoaks, Thrive, Dimension, etc?”
A public-evidence scan of the three named firms — one profile per firm covering recommendation, fit, caveat, capacity, portfolio and recent deals — finds the original shortlist underweighted elite technology and growth investors. All three merit inclusion: Dimension and Thrive join Wave 1 outright; Greenoaks joins Wave 1 or early Wave 2 depending on Multiply’s growth and deployment economics. This is strategic fundraising research, not investment, legal, or securities advice.
Hover a column for the named portfolio companies and deals behind each assessment. The fit bar reads direct thesis fit to AI robotics for GMP biomanufacturing, from the qualitative evidence — not a market score.
Revised priority among the three: Wave 1 Wave 1 / early Wave 2, conditional on software-like growth metrics
First 6–8 meetings now include Dimension and Thrive; Greenoaks joins that opening group only if Multiply can show software-like growth and repeatable deployment economics, otherwise it follows the specialist leads immediately. A particularly credible syndicate: Dimension or a top life-sciences specialist paired with Thrive or Greenoaks.
| # | Firm | Recommendation | Why it fits | Main caveat | Conflict note | Source |
|---|
Strategic fundraising research updating the prior Multiply Labs Series C shortlist; 3 rows, one public-evidence profile per firm (Dimension, Thrive Capital, Greenoaks), compiled from publicly announced financings and third-party fund databases. Transaction facts should be reconfirmed during preparation; blank public-search results are not proof of being conflict-free — formal portfolio, information-barrier, and partner-level conflict checks remain necessary. No confidential or unannounced customer information is used. Full deal and capacity text trimmed for space in the table; hover the comparison for it.